    <!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no">
  <title>Finding Dopa – The Science</title>
  <meta name="description" content="Stem cell therapy offers new hope for Parkinson’s disease. A fix is on the way. Keep fighting!">
  <link rel="icon" href="/favicon.png" type="image/png">
  <link rel="apple-touch-icon" href="/favicon.png">
  <meta name="theme-color" content="#000000">
  <link href="https://fonts.googleapis.com/css2?family=Raleway:wght@700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.0/css/all.min.css">

   <style>

   html, body {
      margin: 0;
      padding: 0;
      font-family: 'Segoe UI', sans-serif;
      background: rgba(0, 0, 0, 0.6);
      color: #222;
      overflow-x: hidden;
    }

	   /*color: #004d40;*/
	   
     .main-content {
  max-width: 700px;
  margin: 0 auto;
    }
	   
    /* Canvas Background */
    #nebula-canvas {
      position: fixed;
      top: 0;
      left: 0;
      width: 100%;
      height: 100%;
      z-index: -1;
      background: transparent;
      pointer-events: none;
    }

    header {
      background-color: #222;
    }

	   /*background-color: #121212;*/

    .top-bar {
      display: flex;
      align-items: center;
      background: #222;
      padding: 6px 10px;
    }

	   /*background: #1a1a1a;*/

     .home-brand {
      display: flex;
      align-items: center;
      gap: 6px;
      text-decoration: none;
      color: #007acc;
      font-size: 1.2rem;
    }

    .home-brand:hover {
      color: #00bfff;
    }

    .logo-text {
      font-family: 'PT Serif', serif;
      font-weight: 700;
      font-size: 1.3rem;
      color: white;
    }

.slider-container {
      width: 100%;
      display: flex;
      gap: 10px;
      padding: 10px;
      overflow-x: auto;
      scrollbar-width: none;
    }

    .slider-container::-webkit-scrollbar {
      display: none;
    }

    .slide {
      flex: 0 0 auto;
      background: #1f1f1f;
      color: white;
      padding: 5px 10px;
      border-radius: 8px;
      white-space: nowrap;
      font-size: 0.95rem;
      font-family: 'PT Serif', serif;
      text-decoration: none;
      text-align: center;
    }
	   
    .slide:hover {
      color: #00bfff;
    }

    .slide.active {
      background: #fdfdfd;
      color: #2e2a89;
      border: 2px solid #2e2a89;
    }

    main {
      display: flex;
      flex-direction: column;
      align-items: center;
      text-align: center;
    }

    .hero {
      font-family: 'Raleway';
      padding: 0 20px;
      margin: -10px 0 1px 0; /* Adjusted margin to move catchphrase higher */
    }

    .hero p {
      max-width: 600px;
      font-size: 1rem;
      padding: 0px 0px 10px 0px;
      color: white;
      margin-bottom: 5px;
      position: relative;
    }

section.hero:first-of-type {
  margin-top: -5px;  /* or adjust to your needs */
}
       
       /*      color: #29ff7a;*/

   /* .hero p::after {
      content: '';
      position: absolute;
      left: 10%;
      right: 10%;
      bottom: -12px;
      border-bottom: 1px solid white;
    }*/

    .welcome-text {
      font-size: 2rem;
      color: #29ff7a;
    }

    .orb-grid {
      display: flex;
      flex-wrap: wrap;
      justify-content: center;
      gap: 20px;
      margin: 10px 0;
      font-family: 'Raleway';
    }

    .orb {
      background: rgba(255, 255, 255, 0.15);
      border: 2px solid #29ff7a;
      border-radius: 50%;
      width: 140px;
      height: 140px;
      display: flex;
      align-items: center;
      justify-content: center;
      color: white;
      font-size: 0.9rem;
      text-align: center;
      padding: 10px;
      cursor: pointer;
      transition: transform 0.3s ease;
      box-shadow: 0 0 12px rgba(255, 255, 255, 0.3);
    }

    .orb:hover {
      transform: scale(1.05);
      box-shadow: 0 0 15px #29ff7a;
    }

    .modal {
      display: none;
      position: fixed;
      z-index: 1000;
      left: 0;
      top: 0;
      width: 100vw;
      height: 100vh;
      overflow: auto;
      background-color: rgba(0,0,0,0.85);
    }

    .modal-content {
      background-color: #1a1a1a;
      margin: 10% auto;
      padding: 20px;
      border: 1px solid #888;
      max-width: 600px;
      color: white;
      font-size: 0.95rem;
      font-family: 'Raleway';
      text-align: left;
      border-radius: 8px;
    }
    
    /*font-family: 'Orbitron', sans-serif;*/

    .close {
      color: #aaa;
      float: right;
      font-size: 24px;
      font-weight: bold;
      cursor: pointer;
    }

    .close:hover,
    .close:focus {
      color: white;
    }

 .hero-section {
   max-width: 500px;
      margin: 0 auto;
  display: flex;
  justify-content: center; /* NEW: ensures image is centered */
  padding: 0 5px; /* NEW: add padding for mobile spacing */
  box-sizing: border-box;
}

.hero-img {
  width: 500px;
  max-width: 100%;
  height: auto;
  display: block;
  border-radius: 12px;
  margin-top: 3px;
}
       
    footer {
      text-align: center;
      padding: 10px 20px;
      background: #1a1a1a;
      color: white;
      font-size: 0.8rem;
    }
  </style>
</head>
<body>
  <!-- Canvas for Particle Animation -->
  <canvas id="nebula-canvas"></canvas>

  <header>
    <div class="top-bar">
      <a href="index.html" class="home-brand" aria-label="Home">
        <i class="fas fa-brain"></i>
        <span class="logo-text">Finding Dopa</span>
      </a>
    </div>
    <div class="slider-container">
      <a href="fix-or-cure.html" class="slide">Fix or Cure?</a>
      <a href="science.html" class="slide">The Science</a>
      <a href="actors.html" class="slide">The Actors</a>
      <a href="news.html" class="slide">Latest News</a>
      <a href="clinical-trials.html" class="slide">Clinical Trials</a>
      <a href="resources.html" class="slide">Resources</a>
      <a href="about.html" class="slide">About</a>
      <a href="disclaimer.html" class="slide">Disclaimer</a>
    </div>
  </header>
<div class="main-content">
  <main>
      
  <section class="hero-section">
    <img src="images/The Science.png" class="hero-img" alt="The Science">
  </section>

      <section class="hero">
      <p>This page lists the building blocks and mechanisms forming the backbone of Parkinson’s research.</p>
      <p>From stem cells to CRISPR gene editing, each entry highlights a key element in how the disease is understood and treated.</p>
      </section>
      
    <section class="orb-grid">
      <div class="orb" onclick="openModal('modal8')">REGENERATE-PD</div>
      <div class="orb" onclick="openModal('modal7')">CRISPR Gene Editing</div>
      <div class="orb" onclick="openModal('modal6')">Fetal vs. Embryonic Stem Cells</div>
      <div class="orb" onclick="openModal('modal5')">hESCs</div>
      <div class="orb" onclick="openModal('modal4')">iPSCs</div>
      <div class="orb" onclick="openModal('modal1')">Nerve Grafts</div>
      <div class="orb" onclick="openModal('modal2')">MSCs</div>
      <div class="orb" onclick="openModal('modal3')">ANPD001</div>
    </section>
  </main>

    <div id="modal8" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal8')">&times;</span>
      <p><strong>REGENERATE-PD</strong></p>
      <p>- A new gene therapy approach for Parkinson’s disease is being tested in a Phase 2 clinical trial called REGENERATE-PD, which is currently recruiting participants. The treatment involves delivering the GDNF gene (Glial cell line-Derived Neurotrophic Factor) into the putamen, a brain region severely affected in Parkinson’s, using a viral vector called AAV2 (Adeno-Associated Virus serotype 2). The trial is randomized, double-blind, and surgically controlled, meaning that some participants undergo a sham surgery to help researchers assess true effectiveness while maintaining scientific rigor.</p>
      <p>- AAV2 serves as a delivery vehicle, inserting the GDNF gene into living brain cells. Once inside, these cells begin producing GDNF, a protein known to support the survival, function, and potential regeneration of dopamine-producing neurons. The therapy aims to protect these vulnerable cells and enhance their performance in moderate-stage Parkinson’s patients—those who still retain enough living dopaminergic neurons to benefit from the treatment. It’s not a cure, but a strategy to slow progression or restore some motor function by keeping neurons alive and working longer.</p>
      <p>- Importantly, gene therapy only works on living cells—it cannot revive neurons that have already died. That’s why the trial targets moderate-stage patients, where enough viable neurons remain to respond to GDNF. Previous attempts to use GDNF in Parkinson’s faced delivery challenges, but this study improves on past designs by using direct brain surgery to infuse the therapy precisely into the putamen. Early trials have shown promising safety data, and this Phase 2 study is now testing whether it actually helps patients in real-world clinical terms.</p>
    </div>
  </div>

    <div id="modal7" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal7')">&times;</span>
      <p><strong>CRISPR Gene Editing</strong></p>
      <p>- CRISPR gene editing is a revolutionary tool that allows scientists to precisely modify DNA within living cells. It works like molecular scissors, guided by RNA to a specific DNA sequence, where it can cut and either disable a gene, correct a mutation, or insert new genetic material. This technology has rapidly advanced genetic research and therapy development due to its accuracy, efficiency, and versatility.</p>
      <p>- In relation to Parkinson’s disease (PD), CRISPR offers promising avenues for both research and treatment. PD is often associated with the loss of dopamine-producing neurons and, in some cases, with specific genetic mutations like those in the LRRK2 or SNCA genes. By using CRISPR to correct or silence these mutations in cells or even in the brain, scientists may be able to halt or slow the progression of the disease at its root, rather than just treating symptoms.</p>
      <p>- While this approach is still largely experimental, early studies in lab models have shown success in using CRISPR to correct PD-related mutations and protect neurons. If safety and precision challenges can be fully addressed, CRISPR-based therapies could one day offer a curative, gene-targeted solution to certain forms of Parkinson’s disease.</p>
    </div>
  </div>

<div id="modal6" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal6')">&times;</span>
      <p><strong>Fetal vs. Embryonic Stem Cells</strong></p>
      <p>- Embryonic stem cells are derived from blastocysts (early-stage embryos, typically 4–5 days old). Since they are pluripotent, they can become any type of cell in the body, making them incredibly valuable for regenerative medicine.</p> 
      <p>- Fetal stem cells, on the other hand, are obtained from a developing fetus, usually from tissue discarded after abortion procedures or miscarriages. These cells are more specialized (multipotent), meaning their potential to transform is somewhat limited compared to embryonic stem cells.</p>
      <p>The main ethical concern surrounding embryonic stem cells is the destruction of embryos to obtain them, which raises moral debates about the status of early-stage life. Some believe that this process is equivalent to taking human life, while others argue that using embryos for medical progress outweighs this concern, especially if the embryos were never going to develop into full-term pregnancies. Fetal stem cells are generally less controversial because they are sourced from tissues that would otherwise be discarded, but ethical concerns still exist, particularly surrounding consent and sourcing practices.</p>
      <p>Mass Production & Therapeutic Applications</p>
      <p>- Embryonic stem cells can be grown and reproduced extensively in laboratories, making them ideal for large-scale therapies.</p>
      <p>- Fetal stem cells are harder to mass-produce, as they have already begun differentiating into specific cell types. Nonetheless, they are used in research for treating conditions like Parkinson’s disease, spinal cord injuries, and degenerative disorders.</p>
    </div>
  </div>

<div id="modal5" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal5')">&times;</span>
      <p><strong>hESCs</strong></p>
      <p>Human embryonic stem cells (hESCs) are pluripotent cells derived from early-stage embryos, meaning they have the ability to develop into any cell type in the body, including dopamine-producing neurons lost in Parkinson’s Disease (PD). This makes them a powerful tool for regenerative therapies aimed at replacing the damaged or dead neurons in the brains of PD patients.</p>
      <p>In PD, researchers can guide hESCs in the lab to become dopaminergic neurons—the specific type of neuron that degenerates in the disease. Once transplanted into the brain, these lab-grown neurons can potentially integrate into the patient’s neural circuitry and restore lost dopamine signaling, which is critical for movement control. Preclinical studies in animals have shown that hESC-derived neurons can survive, connect to existing brain structures, and improve motor function.</p>
      <p>Clinical trials are now underway to test the safety and effectiveness of these transplants in humans. While promising, hESC-based therapies come with ethical considerations due to their embryonic origin, and technical challenges such as preventing immune rejection or uncontrolled growth. Still, if successful, hESC-derived cell replacement could represent a true disease-modifying treatment for Parkinson’s Disease.</p>
    </div>
  </div>
    
<div id="modal4" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal4')">&times;</span>
      <p><strong>iPSCs</strong></p>
      <p>Induced pluripotent stem cells (iPSCs) have become a powerful tool in Parkinson’s disease (PD) research due to their ability to generate patient-specific neurons. Scientists can take a small sample of skin or blood from a person with Parkinson’s and reprogram those cells into iPSCs. These iPSCs can then be directed to become dopamine-producing neurons—the very type of cells that degenerate in PD. This allows researchers to study the patient’s specific form of the disease in a dish, offering valuable insights into the underlying causes and progression of PD at a cellular level.</p>
      <p>Beyond disease modeling, iPSCs hold promise for drug discovery and personalized medicine. By testing potential drugs on neurons derived from a patient’s own iPSCs, researchers can identify which treatments are most effective for that individual, potentially leading to more targeted therapies. Moreover, this platform enables the screening of compounds to find new drugs that protect or restore dopamine neurons, reducing reliance on animal models and speeding up the research process.</p>
      <p>Looking forward, iPSCs may also revolutionize treatment through regenerative medicine. There is ongoing research into transplanting dopamine neurons derived from iPSCs into the brains of people with Parkinson’s. Early trials are exploring whether these lab-grown neurons can integrate into the brain and restore lost function. While challenges remain—such as ensuring safety, preventing immune rejection, and controlling cell behavior—iPSCs represent a hopeful path toward reversing the effects of PD, not just managing its symptoms.</p>
    </div>
  </div>

  <div id="modal1" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal1')">&times;</span>
      <p><strong>Nerve Grafts</strong></p>
      <p>The dopaminergic cells being used in research for Parkinson’s Disease usually come from stem cells — either embryonic stem cells or induced pluripotent stem cells (iPSCs). iPSCs are adult cells (often skin or blood cells) that scientists reprogram to become stem cells, then guide them to become dopamine-producing neurons, similar to the ones lost in Parkinson’s.</p>
      <p></p>These lab-grown cells are promising because they can be made in large numbers and function like real dopamine neurons. However, since they often come from sources other than the patient, they could be attacked by the immune system. That’s why researchers are testing nerve grafts — to protect these new cells and help them survive once implanted in the brain.</p>
      <p></p>This combined approach is still in the clinical trial and experimental stage, but early results are encouraging, and it’s considered one of the most exciting frontiers in Parkinson’s therapy.</p>
    </div>
  </div>

  <div id="modal2" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal2')">&times;</span>
      <p><strong>MSCs (Mesenchymal Stem/Stromal Cells)</strong></p>
      <p>MSCs are multipotent cells typically derived from bone marrow, fat tissue, or umbilical cord blood. They have gained attention for their regenerative and immunomodulatory properties, making them a promising candidate for treating neurodegenerative diseases like Parkinson’s Disease (PD). Unlike neural stem cells, MSCs do not naturally become neurons in large numbers, but they can still influence the brain environment in beneficial ways.</p>
      <p>In PD, MSCs are thought to help primarily through their secretion of protective molecules—called trophic factors—that support neuron survival and reduce inflammation. These cells can home in on damaged brain areas and release signals that promote repair, protect dopamine-producing neurons, and modulate immune responses. Studies have shown that MSCs can reduce microglial activation (a marker of neuroinflammation), which is a significant contributor to ongoing neuronal loss in PD.</p>
      <p>Although MSCs are not a direct replacement for lost dopamine neurons, early trials suggest they may slow progression or improve symptoms by creating a more favorable brain environment. Researchers are continuing to explore ways to enhance their effects, such as by engineering MSCs to produce more dopamine-supporting factors or deliver genes.</p>
    </div>
  </div>

   <div id="modal3" class="modal">
    <div class="modal-content">
      <span class="close" onclick="closeModal('modal3')">&times;</span>
      <p><strong>ANPD001</strong></p>
      <p>ANPD001 is an investigational autologous dopaminergic neuronal precursor cell (DANPC) therapy being developed by Aspen Neuroscience for the treatment of Parkinson's disease.</p>
<p>•	August 8, 2023:
The U.S. Food and Drug Administration (FDA) clears Aspen’s Investigational New Drug (IND) application, allowing the initiation of clinical trials for ANPD001.  
	<br>•	October 19, 2023:
ANPD001 receives Fast Track Designation from the FDA, facilitating expedited development and review processes.
	<br>•	January 23, 2024:
Launch of the ASPIRO Phase 1/2a clinical trial, the first multicenter study of an autologous iPSC-derived therapy in the U.S., aimed at assessing safety, tolerability, and preliminary efficacy in patients with moderate to severe Parkinson’s disease.  
	<br>•	January 13, 2025:
Aspen announces the successful completion of dose escalation and the first two patient cohorts in the ASPIRO trial, with no serious adverse events reported.  
	<br>•	May 2025:
Six-month interim results indicate that ANPD001 is well-tolerated, with early improvements observed in motor function and quality of life measures.  
	<br>•	October 30, 2025 (estimated):
Primary completion date for the ASPIRO Phase 1/2a trial, marking the end of the main study period.
	<br>•	Late 2026 – Early 2027 (projected):
Potential initiation of a Phase 3 clinical trial, contingent upon positive outcomes from the Phase 1/2a trial and subsequent regulatory discussions.
	<br>•	2029–2030 (projected):
Possible FDA approval and market entry for ANPD001, assuming successful completion of clinical trials and regulatory review.
	<br>•	April 30, 2030 (estimated):
Final completion date for the ASPIRO Phase 1/2a trial, including long-term follow-up assessments.</p>
    </div>
  </div>
</div>
  <footer>
    &copy; 2025 Finding Dopa. All rights reserved.
  </footer>
  
  <script>
  function openModal(id) {
    document.getElementById(id).style.display = 'block';
  }

  function closeModal(id) {
    document.getElementById(id).style.display = 'none';
  }

  // Highlight current page
  const currentPage = window.location.pathname.split("/").pop();
  document.querySelectorAll('.slider-container .slide').forEach(slide => {
    if (slide.getAttribute('href') === currentPage) {
      slide.classList.add('active');
    }
  });

  // Particle Animation
  const canvas = document.getElementById('nebula-canvas');
  const ctx = canvas.getContext('2d');
  let particlesArray;

  function resizeCanvas() {
    canvas.width = window.innerWidth;
    canvas.height = window.innerHeight;
    // Fill with solid black once at the beginning
    ctx.fillStyle = 'black';
    ctx.fillRect(0, 0, canvas.width, canvas.height);
  }

  window.addEventListener('resize', resizeCanvas);
  resizeCanvas();

  class Particle {
    constructor() {
      this.reset();
    }

    reset() {
      this.x = Math.random() * canvas.width;
      this.y = Math.random() * canvas.height;
      this.size = Math.random() * 2 + 1;
      this.speedX = Math.random() * 0.5 - 0.25;
      this.speedY = Math.random() * 0.5 - 0.25;
      this.opacity = Math.random();
      this.color = `rgba(41, 255, 122, ${this.opacity})`; // green glow
    }

    update() {
      this.x += this.speedX;
      this.y += this.speedY;

      if (this.x < 0 || this.x > canvas.width || this.y < 0 || this.y > canvas.height) {
        this.reset();
      }
    }

    draw() {
      ctx.beginPath();
      ctx.arc(this.x, this.y, this.size, 0, Math.PI * 2);
      ctx.fillStyle = this.color;
      ctx.fill();
    }
  }

  function initParticles() {
    particlesArray = [];
    const numberOfParticles = 150;
    for (let i = 0; i < numberOfParticles; i++) {
      particlesArray.push(new Particle());
    }
  }

  function animateParticles() {
    // Instead of clearing, paint a semi-transparent black layer
    ctx.fillStyle = 'rgba(0, 0, 0, 0.1)';
    ctx.fillRect(0, 0, canvas.width, canvas.height);

    particlesArray.forEach(particle => {
      particle.update();
      particle.draw();
    });

    requestAnimationFrame(animateParticles);
  }

  initParticles();
  animateParticles();
</script>
</body>
</html>
